James A. Bolognese

7.5k total citations · 1 hit paper
71 papers, 5.7k citations indexed

About

James A. Bolognese is a scholar working on Pharmacology, Rheumatology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, James A. Bolognese has authored 71 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Pharmacology, 13 papers in Rheumatology and 12 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in James A. Bolognese's work include Inflammatory mediators and NSAID effects (26 papers), Pain Mechanisms and Treatments (10 papers) and Statistical Methods in Clinical Trials (9 papers). James A. Bolognese is often cited by papers focused on Inflammatory mediators and NSAID effects (26 papers), Pain Mechanisms and Treatments (10 papers) and Statistical Methods in Clinical Trials (9 papers). James A. Bolognese collaborates with scholars based in United States, United Kingdom and Japan. James A. Bolognese's co-authors include Hui Quan, John A. Baron, Robert S. Sandler, Robert H. Riddell, Bettina Oxenius, Robert S. Bresalier, Kevin Horgan, Ángel Lanas, Dion Morton and Marvin A. Konstam and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

James A. Bolognese

70 papers receiving 5.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial

2005 1.9k citations Robert S. Bresalier, Robert S. Sandler et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by James A. Bolognese

Since Specialization

Citations

This map shows the geographic impact of James A. Bolognese's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James A. Bolognese with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James A. Bolognese more than expected).

Fields of papers citing papers by James A. Bolognese

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James A. Bolognese. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James A. Bolognese. The network helps show where James A. Bolognese may publish in the future.

Co-authorship network of co-authors of James A. Bolognese

This figure shows the co-authorship network connecting the top 25 collaborators of James A. Bolognese. A scholar is included among the top collaborators of James A. Bolognese based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James A. Bolognese. James A. Bolognese is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Effects of orally administered crofelemer on the incidence and severity of neratinib-induced diarrhea in female dogs 2024 ·PLoS ONE ·(unknown), A.G.V. Teixeira, (unknown), Carol Meschter, James A. Bolognese, Pravin Chaturvedi	0
2	Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis 2023 ·Nature Medicine ·Arun J. Sanyal, Sudha S. Shankar, Katherine P. Yates, James A. Bolognese, (unknown), (unknown), Brent A. Neuschwander‐Tetri, Kris V. Kowdley, Raj Vuppalanchi, Cynthia Behling, James Tonascia, Anthony E. Samir, Claude B. Sirlin, Sarah P. Sherlock, Kathryn J. Fowler, Helen Heymann, Tania N. Kamphaus, Rohit Loomba, Roberto A. Calle	60
3	Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosis 2018 ·Journal of Cystic Fibrosis ·Isabelle Sermet‐Gaudelus, John P. Clancy, David P. Nichols, Jerry A. Nick, K. De Boeck, George M. Solomon, Marcus Mall, James A. Bolognese, Florilène Bouisset, (unknown), (unknown), (unknown), Noreen Henig, J.S. Elborn, Steven M. Rowe	43
4	Prolonged joint residency of triamcinolone acetonide after an intra-articular injection of FX006, a sustained release formulation for the treatment of osteoarthritis 2015 ·Osteoarthritis and Cartilage ·N. Bodick, Joelle Lufkin, (unknown), (unknown), Anjali S. Kumar, (unknown), James A. Bolognese, (unknown), Michael D. Clayman	4
5	Early Clinical Development Planning via Biomarkers, Clinical Endpoints, and Simulation: A Case Study to Optimize for Phase 3 Dose Selection 2014 ·Therapeutic Innovation & Regulatory Science ·Bret J. Musser, James A. Bolognese, (unknown), (unknown), Yue Shentu, A. Ederveen, Lori Mixson, Nitin Patel	1
6	Safety and efficacy of FX006 in patients with osteoarthritis of the knee 2014 ·Osteoarthritis and Cartilage ·N. Bodick, Joelle Lufkin, (unknown), Anjali S. Kumar, James A. Bolognese, (unknown), David J. Hunter, Michael D. Clayman	2
7	The Pain Quality Response Profile of Pregabalin in the Treatment of Neuropathic Pain 2011 ·Clinical Journal of Pain ·Mark P. Jensen, Arnold R. Gammaitoni, James A. Bolognese, Achilles Alon, Steven S. Smugar, Bradley S. Galer, David Hewitt	17
8	A walking model to assess the onset of analgesia in osteoarthritis knee pain 2010 ·Osteoarthritis and Cartilage ·Elena Peeva, Chan Beals, James A. Bolognese, Alan Kivitz, (unknown), (unknown), Steven S. Smugar, R. W. Moskowitz	11
9	Single-dose effects of isosorbide mononitrate alone or in combination with losartan on central blood pressure 2010 ·Journal of the American Society of Hypertension ·(unknown), Irene Nunes, James A. Bolognese, Deborah L. Miller, (unknown), (unknown), William B. Smith, Gary Herman, Peter U. Feig	6
10	Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) Study Program: Cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis 2006 ·American Heart Journal ·Christopher P. Cannon, Sean Curtis, James A. Bolognese, Loren Laine	51
11	A Randomized Trial of Rofecoxib for the Chemoprevention of Colorectal Adenomas 2006 ·Gastroenterology ·John A. Baron, Robert S. Sandler, Robert S. Bresalier, Hui Quan, Robert H. Riddell, Ángel Lanas, James A. Bolognese, Bettina Oxenius, Kevin Horgan, Susan Loftus, Dion Morton	325
12	Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial breakdown → 2005 ·New England Journal of Medicine ·Robert S. Bresalier, Robert S. Sandler, Hui Quan, James A. Bolognese, Bettina Oxenius, Kevin Horgan, Christopher Lines, Robert H. Riddell, Dion Morton, Ángel Lanas, Marvin A. Konstam, John A. Baron	1855
13	The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis 2005 ·Current Medical Research and Opinion ·Dena Rosen Ramey, Douglas J. Watson, Chang Yu, James A. Bolognese, Sean Curtis, Alise Reicin	59
14	Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs* 2004 ·Current Medical Research and Opinion ·(unknown), James A. Bolognese, Chang Yu, David Krupa, Sean Curtis	15
15	Response relationship of VAS and Likert scales in osteoarthritis efficacy measurement 2003 ·Osteoarthritis and Cartilage ·James A. Bolognese, Thomas J. Schnitzer, Elliot Ehrich	113
16	Comparison of rheumatoid arthritis clinical trial outcome measures: A simulation study 2003 ·Arthritis & Rheumatism ·Jennifer J. Anderson, James A. Bolognese, David T. Felson	28
17	Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials 2001 ·Alimentary Pharmacology & Therapeutics ·Christopher J. Hawkey, Loren Laine, S. E. Harper, (unknown), James A. Bolognese, Eric Mortensen, (unknown)	49
18	A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects 2000 ·The American Journal of Medicine ·Richard H. Hunt, Barry M. Bowen, Eric Mortensen, Thomas Simon, Cindy James, A Cagliola, Hui Quan, James A. Bolognese	63
19	Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial 2000 ·Arthritis & Rheumatism ·Christopher J. Hawkey, Loren Laine, Thomas Simon, André Beaulieu, José A. Maldonado‐Cocco, Eduardo Acevedo, Aditi Shahane, Hui Quan, James A. Bolognese, Eric Mortensen	280
20	Effects of finasteride on health-related quality of life in men with symptomatic benign prostatic hyperplasia 1996 ·The Prostate ·Cynthia J. Girman, (unknown), Charles Liss, James A. Bolognese, Bruce Binkowitz, Elizabeth Stoner	34

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact